Who is the CEO of Protia?

According to the DART company overview, Protia's representative director is 임국진 (name as registered in Korean). The company was founded on 2000-03-22.

Where is Protia listed?

Protia trades on the Korea Exchange KOSDAQ market under the ticker 303360. Its fiscal year ends in December.

Does Protia pay a dividend?

Protia did not pay a cash dividend for fiscal 2025, according to its annual report.

Does Protia have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Profit +50% (latest quarterly operating profit up more than 50% year on year); Op. margin 20%+ (operating margin of 20% or more on quarterly revenue of at least ₩5bn); Bonus issue (bonus share issue decided in the past 90 days). These are factual flags, not investment advice.

Which companies are in the same industry as Protia?

Under the Korean Standard Industrial Classification recorded on DART, Protia is grouped with 69 other listed companies in medical devices. The most covered in Korean news over the past 30 days are Ray, CG MedTech and Sky Labs.

Protia KRX:303360KOSDAQ

프로티아 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h0

Articles, 7 days0

DART filings, 7 days0

Articles tracked5since Sep 11

In Q2 2026, Protia reported revenue of ₩5.3bn, up 39.1% year on year, and operating profit of ₩1.6bn. Protia (프로티아) appeared in 0 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 29 with 5 articles. The most common catalyst was risk & warnings (1).

Filing signals Profit +50% Op. margin 20%+ Bonus issue Screener

Protia quarterly results separate, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩5.3bn	+39.1%	₩1.6bn margin 30.6%	₩1.6bn
Q1 2026	₩3.8bn	+41.8%	₩760m margin 19.9%	₩978m
Q4 2025 derived	₩4.5bn	+54.2%	₩1.1bn margin 24.0%	₩1.7bn
Q3 2025	₩4.0bn	+36.9%	₩1.2bn margin 29.1%	₩1.3bn
Q2 2025	₩3.8bn	+56.6%	₩1.0bn margin 27.1%	₩787m
Q1 2025	₩2.7bn	+24.5%	₩412m margin 15.3%	₩714m
Q4 2024 derived	₩2.9bn	+27.4%	₩553m margin 18.7%	₩1.0bn
Q3 2024	₩2.9bn	+41.9%	₩540m margin 18.3%	₩351m

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Protia top stories 2 weeks, by number of outlets

1
프로티아, 50% 무상증자 단행...‘주주환원 원년 선언’
1 outlets · 2 articlesFirst report Sep 29 14:51 이데일리
2
[공시] 프로티아 주권매매거래정지 (무상증자)
1 outlets · 1 articlesFirst report Sep 29 12:42 스페셜타임스Negative news
3
프로티아, 50% 무상증자 결정…643만9857주 신주 발행
1 outlets · 1 articlesFirst report Sep 29 12:44 CBC뉴스
4
프로티아, 50% 무상증자 결정…"주주환원 단계적 확대"
1 outlets · 1 articlesFirst report Sep 29 17:29 뉴스핌

Latest Protia news Korean headlines

Sep 2917:29

프로티아, 50% 무상증자 결정…"주주환원 단계적 확대"
뉴스핌
Sep 2914:52
프로티아, 50% 무상증자 단행...‘주주환원 원년 선언’
이데일리
1 more on this story · 1 outlets
- 프로티아, 50% 무상증자 단행...‘주주환원 원년 선언’이데일리 · Sep 29 14:51
Sep 2912:44

Breaking프로티아, 50% 무상증자 결정…643만9857주 신주 발행
CBC뉴스
Sep 2912:42

Major[공시] 프로티아 주권매매거래정지 (무상증자)
스페셜타임스Negative news

Articles per day 2 weeks

529

Company profile

CEO: 임국진
Industry: Medical devices
Founded: 2000-03-22
Fiscal year-end: December
Head office: 서울특별시 강서구
Website: protia.co.kr
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Same industry Medical devices

All in industry

Company	Latest quarter op. profit	Articles 30d
Ray	₩5.7bn	85
CG MedTech	₩333m	79
Sky Labs	–	71
Won Tech	₩11.1bn	32
Seers	₩12.9bn	31
Cosmo Robotics	−₩3.3bn	28
Medyssey	–	27
Dio	₩4.4bn	22

Compare Protia side by side with these companies

Protia DART filings

Sep 2913:37

Other 주주명부폐쇄기간또는기준일설정
Other
Sep 2912:16

Bonus issue 주요사항보고서(무상증자결정)
Capital & M&A
Sep 2912:16

Trading halt / delisting 주권매매거래정지 (무상증자)
Risk & warnings

Catalysts 2 weeks

Risk & warnings1

Mentioned alongside 2 weeks

No co-mentioned companies yet.

Protia FAQ

Who is the CEO of Protia?: According to the DART company overview, Protia's representative director is 임국진 (name as registered in Korean). The company was founded on 2000-03-22.
Where is Protia listed?: Protia trades on the Korea Exchange KOSDAQ market under the ticker 303360. Its fiscal year ends in December.
What were Protia's latest quarterly results?: In Q2 2026, Protia reported revenue of ₩5.3bn, up 39.1% year on year, and operating profit of ₩1.6bn. Figures come from reports filed on DART.
Does Protia pay a dividend?: Protia did not pay a cash dividend for fiscal 2025, according to its annual report.
Does Protia have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Profit +50% (latest quarterly operating profit up more than 50% year on year); Op. margin 20%+ (operating margin of 20% or more on quarterly revenue of at least ₩5bn); Bonus issue (bonus share issue decided in the past 90 days). These are factual flags, not investment advice.
Which companies are in the same industry as Protia?: Under the Korean Standard Industrial Classification recorded on DART, Protia is grouped with 69 other listed companies in medical devices. The most covered in Korean news over the past 30 days are Ray, CG MedTech and Sky Labs.